Bones and Crohn’s: No benefit of adding sodium fluoride or ibandronate to calcium and vitamin D

Table 2 Bone mineral density of spine and femur, in- and between-group change

Lumbar spine		Baseline		First year		Second year		Third year
Group A calcium/vitamin D	n (%)	32		27 (84.4)		22 (68.6)		14 (43.8)
	T-score	-1.57 ± 0.31		-1.32 ± 0.42b		-1.21 ± 0.49b		-1.18 ± 0.36b
	Δ T-score (95% CI)		+0.28 ± 0.35 (0.162–0.460)		+0.33 ± 0.49 (0.109-0.558)		+0.43 ± 0.47 (0.147–0.708)
	BMD	0.90 ± 0.04		0.92 ± 0.05		0.94 ± 0.05		0.94 ± 0.04
Group B + sodium fluoride	n (%)	62		47 (75.8)		36 (58.0)		30 (48.4)
	T-score	-1.82 ± 0.75h		-1.60 ± 0.84d		-1.40 ± 1.01d		-1.37 ± 0.95d
	Δ T-score (95% CI)		+0.22 ± 0.33 (0.125–0.321)		+0.47 ± 0.60 (0.262–0.676)		+0.51 ± 0.44 (0.338–0.682)
	BMD	0.87 ± 0.08		0.88 ± 0.09		0.90 ± 0.11		0.91 ± 0.11
Group C + ibandronate	n (%)	54		49 (90.1)		34 (63.0)		27 (50)
	T-score	-1.89 ± 0.71		-1.69 ± 0.78e		-1.61 ± 0.83e		-1.56 ± 0.78f
	Δ T-score (95% CI)		+0.22 ± 0.38 (0.111– 0.329)		+0.36 ± 0.53 (0.147–0.578)		+0.41 ± 0.48 (0.238–0.576)
	BMD	0.85 ± 0.08		0.87 ± 0.08		0.89 ± 0.08		0.90 ± 0.08
Total	n (%)	148		123 (83.1)		92 (62.2)		71 (47.8)

In-treatment group change, baseline to first, second and third year: Group A, ^bP < 0.01; group B, ^dP < 0.01; group C, ^eP < 0.025, ^fP < 0.01; Between-treatment groups: ^hP < 0.01, group A vs group C. BMD: Bone mineral density.